Skip to main navigation Skip to search Skip to main content

Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease

  • Leen J M Seys
  • , Fien M Verhamme
  • , Anja Schinwald
  • , Hamida Hammad
  • , Danen Mootoosamy Cunoosamy
  • , Claudie Bantsimba-Malanda
  • , Alan Sabirsh
  • , Eileen McCall
  • , Liz Flavell
  • , Ronald Herbst
  • , Sharen Provoost
  • , Bart N Lambrecht
  • , Guy F Joos
  • , Guy G Brusselle
  • , Ken R Bracke
  • Ghent University Hospital
  • AstraZeneca Respiratory, Inflammation and Autoimmune iMed Biotech Unit
  • Laboratory of Immunoregulation and Mucosal Immunity, Department for Molecular Biomedical Research, VIB
  • Department of Research, MedImmune, LLC
  • AstraZeneca Cardiovascular and Metabolic Disease iMed Biotech Unit
  • AstraZeneca Discovery Sciences iMed Biotech Unit

Research output: Contribution to journalArticlepeer-review

Abstract

RATIONALE: B cell-activating factor (BAFF) plays a major role in activation of B cells and in adaptive humoral immune responses. In chronic obstructive pulmonary disease (COPD), lymphoid follicles have been associated with disease severity, and overexpression of BAFF has been demonstrated within lymphoid follicles of patients with severe COPD.

OBJECTIVES: To investigate expression and localization of BAFF in the lungs of patients with COPD and to study the role of BAFF in COPD by antagonizing BAFF in a mouse model of chronic cigarette smoke (CS) exposure.

METHODS: We quantified and localized BAFF expression in lungs of never-smokers, smokers without COPD, and patients with COPD and in lungs of air- or CS-exposed mice by reverse-transcriptase polymerase chain reaction, ELISA, immunohistochemistry, and confocal imaging. Next, to investigate the role of BAFF in COPD, we antagonized BAFF by prophylactic or therapeutic administration of a soluble fusion protein of the BAFF-receptor, BAFFR-Fc, in mice exposed to air or CS for 24 weeks and evaluated several hallmarks of COPD and polarization of lung macrophages.

MEASUREMENTS AND MAIN RESULTS: BAFF expression was significantly increased in lungs of patients with COPD and CS-exposed mice. BAFF staining in lymphoid follicles was observed around B cells, CD4(+) cells, dendritic cells, follicular dendritic cells, and fibroblastic reticular cells. Prophylactic and therapeutic administration of BAFFR-Fc in mice reduced pulmonary B-cell numbers and prevented CS-induced formation of lymphoid follicles and increases in immunoglobulin levels. Interestingly, prophylactic BAFFR-Fc administration significantly attenuated pulmonary inflammation and destruction of alveolar walls. Moreover, antagonizing BAFF altered the phenotype of alveolar and interstitial macrophages.

CONCLUSIONS: BAFF is significantly increased in lungs of patients with COPD and is present around both immune and stromal cells within lymphoid follicles. Antagonizing BAFF in CS-exposed mice attenuates pulmonary inflammation and alveolar destruction.

Original languageEnglish
Pages (from-to)706-18
Number of pages13
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume192
Issue number6
DOIs
Publication statusPublished - 15 Sept 2015

Keywords

  • Adaptive Immunity
  • Aged
  • Animals
  • B-Cell Activating Factor/antagonists & inhibitors
  • B-Lymphocytes/immunology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunohistochemistry
  • Lung/immunology
  • Lymphoid Tissue/metabolism
  • Macrophages/immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive/immunology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Smoke/adverse effects
  • Smoking/adverse effects

Classification according to Österreichische Systematik der Wissenschaftszweige (ÖFOS 2012)

  • Not applicable

Applied Research Level (ARL)

  • Not applicable

Research focus/foci

  • Not applicable

Fingerprint

Dive into the research topics of 'Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease'. Together they form a unique fingerprint.

Cite this